Khosla Impact, established in 2013, is an impact investment firm based in Menlo Park, California. It focuses on assisting high-impact entrepreneurs who develop products and services for the three billion people at the bottom of the world's economic pyramid. The firm invests in for-profit enterprises serving low-income individuals and small businesses in emerging markets, with a primary focus on South Asia. Khosla Impact encourages experimentation and supports entrepreneurs passionate about solving socio-economic challenges through technology and innovative business models.
Science is a startup company that develops technologies for a range of serious unmet medical needs.
Tempero Bio
Series B in 2025
Tempero Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment and prevention of substance use disorders. The company aims to address the challenges faced by individuals struggling with addiction, providing transformative solutions that help patients overcome treatment obstacles and support their recovery journey. Through its specialized approach, Tempero Bio is dedicated to improving the lives of those affected by substance use disorders and related conditions.
C the Signs
Venture Round in 2025
C the Signs is a cancer prediction system that empowers general practitioners to identify patients at risk of cancer in its early and treatable stages. The platform provides an easy-to-use format for simultaneously checking combinations of signs, symptoms, and risk factors during patient consultations, when decision-making capabilities are most impactful. By analyzing various clinical data points, C the Signs aids physicians in recommending necessary investigations or urgent referrals in under 30 seconds, thereby facilitating timely diagnosis and treatment. The company's mission is to enhance patient outcomes by fast-tracking individuals to appropriate tests or referrals, ultimately aiming to reduce cancer-related mortality rates.
Clear Labs
Series D in 2025
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
HealthifyMe
Series D in 2024
HealthifyMe is a fitness application designed to help users achieve their health and weight loss objectives through their computers and smartphones. Launched in 2012 by a team of doctors, nutritionists, and fitness trainers in Bangalore, India, the app allows users to track their calorie intake, monitor nutrition and fitness activities, and assess their weight to determine overall health. With features that enable users to set and work towards healthy goals, the platform also facilitates data sharing with experts, who provide personalized advice and recommendations. The application is enhanced by an artificial intelligence-powered fitness coach that leverages automated analytics, making it easier for users to receive tailored online fitness consultations and achieve their health aspirations.
Even
Series A in 2024
Even is a health tech company that collaborates with leading hospitals to provide comprehensive healthcare services through a subscription model. Its offerings include unlimited diagnostics, consultations, and hospitalization coverage valued at up to 50 lakh. The company simplifies the reimbursement process by directly transferring funds to partner hospitals, ensuring a seamless experience for members. By charging a recurring monthly fee, Even aims to address critical long-term health needs for individuals, making healthcare more accessible and manageable.
Neurode
Pre Seed Round in 2024
Neurode is focused on the development of a non-invasive wearable headset aimed at enhancing cognitive performance for individuals with neurological conditions, particularly ADHD. This innovative device employs electrical stimulation to address the imbalances in brain activity commonly associated with ADHD. Alongside the headset, Neurode offers a companion application that monitors users' progress and shares improvements with healthcare professionals. This drug-free approach seeks to alleviate symptoms such as working memory deficits, attention challenges, and impulse control issues, ultimately enabling better management of cognitive performance for users.
Inflammatix
Series E in 2024
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.
Viome Life Sciences
Series D in 2024
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Noetik
Series A in 2024
Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By leveraging self-supervised learning and integrating human multimodal data, the company aims to enhance the effectiveness and personalization of cancer therapies, thereby improving patient outcomes in oncology.
Openwater
Venture Round in 2024
Openwater is a San Francisco-based startup founded in 2016 that focuses on developing advanced medical technology aimed at diagnosing and treating diseases at the cellular level. The company has created a wearable device that leverages novel optoelectronic technology to offer high-resolution imaging capabilities, effectively replacing traditional MRI methods. By utilizing LCDs with small pixels, Openwater's device generates holographic images that minimize scattering and achieve MRI-like resolution. This innovation enables physicians to diagnose and treat diseases by targeting individual cells while preserving the surrounding tissue, thereby enhancing the precision and effectiveness of medical interventions.
Even
Venture Round in 2024
Even is a health tech company that collaborates with leading hospitals to provide comprehensive healthcare services through a subscription model. Its offerings include unlimited diagnostics, consultations, and hospitalization coverage valued at up to 50 lakh. The company simplifies the reimbursement process by directly transferring funds to partner hospitals, ensuring a seamless experience for members. By charging a recurring monthly fee, Even aims to address critical long-term health needs for individuals, making healthcare more accessible and manageable.
Q Bio
Venture Round in 2024
Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.
Sword Health
Secondary Market in 2024
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
Rubedo Life Sciences
Series A in 2024
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.
Nabla Bio
Series A in 2024
Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.
Loyal
Series B in 2024
Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.
Relation Therapeutics
Seed Round in 2024
Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.
CureSkin
Series B in 2024
CureSkin is a Bengaluru-based company founded in 2016 that specializes in AI-powered mobile applications for dermatological care. The app utilizes computer vision technology to analyze user-uploaded photos, identifying various skin issues such as acne, dark spots, scars, and pigmentation. Based on the analysis, CureSkin recommends personalized treatment plans, skincare products, and connects users with dermatologists for follow-up consultations. By offering these services, CureSkin aims to provide accessible and effective skin health solutions, particularly for individuals who may not have easy access to trained professionals.
Siolta Therapeutics
Series C in 2024
Siolta Therapeutics, Inc. is a clinical-stage biotech company based in San Francisco, California, focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016, the company utilizes its expertise in the developing gut microbiome to promote immune tolerance. Siolta's platform includes the development of pharmaceutical-grade anaerobic organisms and microbiome-based diagnostics that support precision medicine. By leveraging insights from human microbiome studies, Siolta Therapeutics aims to create targeted microbial therapeutics that address the underlying causes of inflammatory diseases, enabling a new approach to prevention and treatment.
Limbic
Series A in 2024
Limbic is a London-based company that specializes in mental healthcare technology. Founded in 2017, it develops a software development kit (SDK) that leverages machine learning to analyze heart rate data collected from wearable devices like the Apple Watch, allowing for the assessment of users' emotional states. Limbic also offers psychological therapies for adults, focusing on improving mental health through innovative solutions. Its platform supports healthcare professionals by providing tools for stress detection and facilitating clinical assessments, thereby enhancing the efficacy of psychological therapy. By combining AI technology with wearable devices, Limbic aims to address the growing challenges in mental health care and improve patient outcomes.
TORTUS AI
Seed Round in 2024
TORTUS AI creates and operates an online tool using artificial intelligence for the healthcare industry. It aims to eliminate human error in medicine through clinician co-working with AI. It provides an AI agent for healthcare, a digital worker that can take over all digital tasks from a clinician such as documentation, requesting tests, access and summarizing patient information. Tortus AI was founded in 2022 and is based in London, England.
Moonwalk Biosciences
Series A in 2024
Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company is creating a profiling and engineering technology platform that leverages advanced artificial intelligence to deliver an in-depth understanding of the epigenome in both health and disease. This innovative approach allows healthcare providers to explore new avenues for therapy discovery and facilitates the reprogramming of cells to restore their healthy state. By integrating AI-driven insights, Moonwalk Biosciences aims to transform the landscape of therapeutic development and improve patient outcomes.
Encellin
Series A in 2023
Encellin, Inc. is a biotechnology company based in San Francisco, California, founded in 2015. It specializes in developing innovative cell-based therapeutics, particularly focusing on a novel thin-film cell encapsulation device. This device utilizes advanced thin-film cell delivery technology, which encapsulates and replaces cells, allowing the enclosed cells to operate as smart molecular factories. Encellin's primary mission is to provide effective treatments for patients with chronic diseases, with an initial emphasis on Type 1 diabetes. The company is committed to advancing next-generation therapies through the expertise of its dedicated team.
Forward
Series E in 2023
Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.
Bold
Series A in 2023
Bold is an at-home digital fitness program designed to help older adults live their strongest, happiest, and healthiest lives. As a member, you’ll enjoy instant access to expert trainers, scientific assessments, and personalized workout plans to help you improve your strength, flexibility, and balance — so you can chase the life you want, at any age.
Rejuvenation Technologies
Seed Round in 2023
Rejuvenation Technologies Inc. is a biotechnology company based in Mountain View, California, focused on developing nucleoside-modified telomerase reverse transcriptase messenger RNA to extend telomeres and promote human health. The company's innovative approach involves delivering a telomere extender that encodes telomerase reverse transcriptase, which transiently boosts telomerase activity in cells. This technology aims to enhance the proliferative capacity of cells, potentially addressing age-related diseases and conditions in various medical fields, including hepatic, pulmonary, and immunology. Additionally, Rejuvenation Technologies offers a range of cell therapies that encompass tissue engineering, cell transplants, skin grafts, immunotherapy, and regenerative medicine. Established in 2016, the company is dedicated to advancing solutions in regenerative health.
Viome Life Sciences
Series C in 2023
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
SiPhox Health
Seed Round in 2023
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.
SiPhox Health
Series A in 2023
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.
SURGE Therapeutics
Series B in 2023
SURGE Therapeutics is dedicated to enhancing cancer patient survival through innovative approaches in immunotherapy. The company has developed a proprietary injectable biodegradable hydrogel designed for the prolonged and localized release of cancer immunotherapy following surgical tumor resection. By targeting the administration of treatment to specific areas at the optimal time, SURGE Therapeutics aims to improve the effectiveness of immunotherapy, allowing for both intravenous and intratumoral injections. This technology seeks to disrupt traditional cancer treatment paradigms and provide better outcomes for patients.
Eureka Health
Seed Round in 2023
Helping people with chronic conditions mitigate their symptoms.
HealthifyMe
Series D in 2023
HealthifyMe is a fitness application designed to help users achieve their health and weight loss objectives through their computers and smartphones. Launched in 2012 by a team of doctors, nutritionists, and fitness trainers in Bangalore, India, the app allows users to track their calorie intake, monitor nutrition and fitness activities, and assess their weight to determine overall health. With features that enable users to set and work towards healthy goals, the platform also facilitates data sharing with experts, who provide personalized advice and recommendations. The application is enhanced by an artificial intelligence-powered fitness coach that leverages automated analytics, making it easier for users to receive tailored online fitness consultations and achieve their health aspirations.
TORTUS AI
Seed Round in 2023
TORTUS AI creates and operates an online tool using artificial intelligence for the healthcare industry. It aims to eliminate human error in medicine through clinician co-working with AI. It provides an AI agent for healthcare, a digital worker that can take over all digital tasks from a clinician such as documentation, requesting tests, access and summarizing patient information. Tortus AI was founded in 2022 and is based in London, England.
Gather Health
Series A in 2023
Gather Health is an international healthcare technology company dedicated to empowering patients with chronic diseases to enhance their health. The company specializes in mobile and cloud-based healthcare applications that utilize the latest medical and behavioral change research to motivate and educate patients. By connecting physicians, patients, their families, and patient communities, Gather Health aims to provide continuous and holistic care, ultimately improving health outcomes. The rise in chronic diseases, such as obesity and diabetes, has created a demand for better care, which Gather Health addresses by equipping patients and healthcare providers with effective tools for managing these conditions. Their flagship product, the Gather Health Diabetes platform, has been successfully implemented in cities including Mumbai, Ahmedabad, Hyderabad, Chennai, and Bangalore, showing positive health outcomes for patients and increased efficiency for healthcare providers. Headquartered in Hong Kong, with offices in Beijing, New York, and India, Gather Health's team comprises clinicians, health experts, interaction designers, and engineers experienced in global healthcare.
Tachyon
Series A in 2023
Tachyon Therapeutics is a biotechnology company focused on developing innovative therapeutics for cancer treatment. The firm specializes in creating selective compounds that target significant drug targets within cancer biology, employing advanced methodologies in molecular cancer biology, epigenetics, and cancer stem cell biology. Currently, Tachyon is conducting Phase 1 clinical trials to evaluate the safety, pharmacokinetics, and anti-tumor effectiveness of its lead compound, TACH101, in patients with advanced cancer. The company's research and development efforts aim to unlock new pathways for treating challenging cancer types, ensuring that its programs are advanced in a timely and scientifically rigorous manner.
IgGenix
Series B in 2023
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
Even
Convertible Note in 2022
Even is a health tech company that collaborates with leading hospitals to provide comprehensive healthcare services through a subscription model. Its offerings include unlimited diagnostics, consultations, and hospitalization coverage valued at up to 50 lakh. The company simplifies the reimbursement process by directly transferring funds to partner hospitals, ensuring a seamless experience for members. By charging a recurring monthly fee, Even aims to address critical long-term health needs for individuals, making healthcare more accessible and manageable.
SURGE Therapeutics
Series A in 2022
SURGE Therapeutics is dedicated to enhancing cancer patient survival through innovative approaches in immunotherapy. The company has developed a proprietary injectable biodegradable hydrogel designed for the prolonged and localized release of cancer immunotherapy following surgical tumor resection. By targeting the administration of treatment to specific areas at the optimal time, SURGE Therapeutics aims to improve the effectiveness of immunotherapy, allowing for both intravenous and intratumoral injections. This technology seeks to disrupt traditional cancer treatment paradigms and provide better outcomes for patients.
Viome Life Sciences
Series C in 2022
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Ochre Bio
Series A in 2022
Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.
Proclaim
Series B in 2022
Fresh is a company that specializes in personalized oral care services and the development of solutions aimed at preventing oral diseases. Founded in 2017 by Mike Hanuschik and headquartered in Mountain View, California, Fresh focuses on addressing oral health issues that can lead to serious systemic diseases, such as diabetes, pancreatic cancer, Alzheimer’s, pneumonia, and heart disease. The company’s platform offers innovative remedies to improve oral health and ensure fresh breath for patients, contributing to overall well-being.
Arpeggio Bio
Series A in 2022
Arpeggio Bio, established in 2017 and headquartered in Boulder, Colorado, specializes in developing innovative software that captures snapshots of cellular RNA activity. By combining biological assays with advanced machine learning algorithms, the company enables pharmaceutical and biotechnology firms to understand a drug's mechanism of action at low sequencing depths. Arpeggio Bio's technology reveals intricate biological networks, facilitating more informed therapeutic development.
Prellis Biologics
Series C in 2022
Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.
Faeth Therapeutics
Series A in 2022
Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.
Relation Therapeutics
Seed Round in 2022
Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.
CHARM Therapeutics
Series A in 2022
CHARM Therapeutics is focused on developing innovative medicines using advanced 3D deep learning and drug discovery technologies. The company's platform aims to address undruggable disease targets, providing healthcare professionals with effective treatment options for challenging medical conditions. By leveraging cutting-edge technology, CHARM Therapeutics seeks to create transformative therapies that have the potential to significantly improve patient outcomes.
Ultima Genomics
Venture Round in 2022
Ultima Genomics, founded in 2016 and based in Newark, California, specializes in genome-scale sequencing technology aimed at providing analytical services to enterprises. The company employs an innovative approach using an open substrate that creates a large, low-cost reaction surface, allowing for billions of reads without the need for expensive flow cells or complex fluidics. By integrating specialized sequencing hardware with machine learning, Ultima Genomics ensures reproducible and accurate results, enabling clients to obtain genomic reports rapidly and efficiently. This technology not only enhances the scale of genomic information but also significantly reduces the costs associated with sequencing, thereby facilitating advancements in biology and improvements in human health.
Mirvie
Series B in 2022
Mirvie is a biotech company focused on developing non-invasive tests aimed at improving maternal-fetal health. Founded in 2018 and based in South San Francisco, California, Mirvie offers a medical diagnostic platform that provides actionable insights for mothers and families throughout their pregnancy journey. The company's innovative predictive tests help medical practitioners identify at-risk pregnancies, allowing for timely interventions and enhanced management of pregnancy-related concerns. By prioritizing safety and health, Mirvie seeks to empower families with the information necessary for better pregnancy outcomes.
Loop
Series B in 2022
Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.
turn.bio
Venture Round in 2022
Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.
Scipher Medicine
Series D in 2022
Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.
Faeth Therapeutics
Seed Round in 2022
Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.
Prellis Biologics
Series B in 2021
Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.
Robin Healthcare
Series B in 2021
Robin Healthcare, Inc. is a healthcare technology company that focuses on enhancing the medical industry through innovative software solutions. Founded in 2017 and headquartered in Berkeley, California, with an additional office in Austin, Texas, the company provides a range of services including clinical documentation solutions, medical scribe services, order and medication entry, chart review, billing and coding, and referral management. By integrating technology with trained medical scribes, Robin Healthcare aims to streamline administrative tasks and improve the doctor-patient experience, allowing healthcare professionals to dedicate more time to patient care while maintaining control over their practices.
Nabla Bio
Seed Round in 2021
Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.
Sword Health
Series D in 2021
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
Fountain Therapeutics
Series A in 2021
Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.
ThoughtSpot
Series F in 2021
ThoughtSpot, Inc. is a provider of search-driven analytics designed for enterprises, enabling users to easily search and analyze data, generate instant charts, build reports, and create dashboards. Founded in 2012 and headquartered in Sunnyvale, California, ThoughtSpot serves various sectors including retail, healthcare, financial services, and manufacturing. The company's platform leverages a natural language search interface, allowing users to obtain actionable insights quickly and efficiently. It connects seamlessly with on-premise, cloud, and big data sources, centralizing data management and facilitating intelligent decision-making. Additionally, ThoughtSpot offers low-code integration solutions for developers, enhancing analytics capabilities within existing products and services. With a focus on empowering users to explore data, ThoughtSpot aims to drive growth and improve business outcomes across organizations. The company has expanded its presence globally with locations in multiple countries, including the United Kingdom, Germany, France, India, and Japan.
Viome Life Sciences
Series C in 2021
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Because Market
Series B in 2021
Because Market is a direct-to-consumer personal care company established in 2017, specializing in products tailored for older adults. The company aims to simplify access to essential health and wellness items, including incontinence underwear, pads, skincare, supplements, and walkers. By providing discreet delivery and flexible subscription options, Because Market facilitates the purchasing process for families seeking to support their senior members. With aspirations to become the most trusted brand in this sector, the company has secured over $40 million in funding from prominent venture capital firms, reflecting its commitment to enhancing the lives of older adults and promoting their independence.
Lightship
Series C in 2021
Lightship is a company founded in 2018 that focuses on enhancing access, choice, and equity in clinical trials through decentralized and hybrid clinical services. By leveraging innovations in digital health and technology, Lightship aims to transform the clinical research landscape by improving patient experiences, retention, and trial diversity. The company moves beyond traditional research centers to make clinical studies more accessible, allowing medical research organizations to overcome the barriers and inefficiencies associated with conventional clinical trial models. Its mission centers on placing patients at the forefront, ensuring that clinical research is designed to meet the needs of diverse populations globally.
Loop
Series A in 2021
Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.
Loyal
Series A in 2021
Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.
Vicarious Surgical
Post in 2021
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company focuses on developing advanced robotic systems that enhance the efficiency of minimally invasive surgical procedures. Its innovative surgical robot combines virtual reality with human-like robotics, allowing for greater precision and control during complex surgeries. Designed for abdominal access, the Vicarious Surgical Robotic System features 3D visualization and operates through a single port, which minimizes invasiveness and promotes faster patient recovery. This compact and portable system can be easily integrated into existing operating rooms, aiming to improve patient outcomes and reduce healthcare costs.
Checkr
Series E in 2021
Checkr, Inc. is a technology-driven company focused on the background check industry, offering a comprehensive range of screening services, including criminal record checks, driving checks, and identity verification. Founded in 2014 and headquartered in San Francisco, California, Checkr utilizes advanced technology and data sources to deliver faster and more efficient background checks compared to traditional providers. The company emphasizes fairness and transparency in hiring, enabling businesses across various sectors, including financial services, healthcare, and staffing, to enhance their hiring processes. Checkr also provides compliance services and security solutions, ensuring a secure and streamlined experience for both employers and candidates. With its innovative platform, Checkr aims to improve the overall applicant experience while supporting companies in navigating the complexities of today's workforce dynamics.
House Rx
Seed Round in 2021
House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.
Eight Sleep
Series C in 2021
Eight Sleep, Inc. is a sleep technology company based in New York, focused on improving sleep quality through innovative smart mattresses and related accessories. Founded in 2014, the company manufactures products that include mattresses, sleep trackers, pillows, organic sheets, foundations, and various sleep-related items such as gravity blankets and blue wave glasses. Eight Sleep's mattresses are designed to regulate temperature, adjusting to the body's natural rhythms for optimal comfort, while also tracking health metrics to enhance sleep quality. The company emphasizes the importance of sleep for overall health and daily performance and sells its products primarily through online channels. Formerly known as Morphy, Inc., Eight Sleep has gained recognition as a leader in sleep technology and was honored as one of the Most Innovative Companies in Consumer Electronics by Fast Company in 2018.
Known Medicine
Seed Round in 2021
Known Medicine Inc., founded in 2020 and based in Salt Lake City, Utah, specializes in developing a custom organoid platform designed for tumor sensitivity testing. The company aims to enhance cancer treatment by conducting experiments on tumor responses to drugs in a controlled laboratory setting rather than within the patient’s body. Known Medicine's innovative approach involves breaking down tumor samples into microtumors, which are treated in specialized micro-environments using various methods to identify the most effective treatments. The platform utilizes machine learning-based sensitivity assays and integrates omics data to detect different cell types, including cancerous, stromal, and immune cells. This enables oncologists to analyze multiple microtumors, ultimately helping to determine optimal treatment strategies for individual patients.
Flow Neuroscience
Series A in 2021
Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.
Encellin
Seed Round in 2021
Encellin, Inc. is a biotechnology company based in San Francisco, California, founded in 2015. It specializes in developing innovative cell-based therapeutics, particularly focusing on a novel thin-film cell encapsulation device. This device utilizes advanced thin-film cell delivery technology, which encapsulates and replaces cells, allowing the enclosed cells to operate as smart molecular factories. Encellin's primary mission is to provide effective treatments for patients with chronic diseases, with an initial emphasis on Type 1 diabetes. The company is committed to advancing next-generation therapies through the expertise of its dedicated team.
IgGenix
Series A in 2021
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
Even
Seed Round in 2021
Even is a health tech company that collaborates with leading hospitals to provide comprehensive healthcare services through a subscription model. Its offerings include unlimited diagnostics, consultations, and hospitalization coverage valued at up to 50 lakh. The company simplifies the reimbursement process by directly transferring funds to partner hospitals, ensuring a seamless experience for members. By charging a recurring monthly fee, Even aims to address critical long-term health needs for individuals, making healthcare more accessible and manageable.
HealthifyMe
Series C in 2021
HealthifyMe is a fitness application designed to help users achieve their health and weight loss objectives through their computers and smartphones. Launched in 2012 by a team of doctors, nutritionists, and fitness trainers in Bangalore, India, the app allows users to track their calorie intake, monitor nutrition and fitness activities, and assess their weight to determine overall health. With features that enable users to set and work towards healthy goals, the platform also facilitates data sharing with experts, who provide personalized advice and recommendations. The application is enhanced by an artificial intelligence-powered fitness coach that leverages automated analytics, making it easier for users to receive tailored online fitness consultations and achieve their health aspirations.
Sword Health
Series C in 2021
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
Ochre Bio
Seed Round in 2021
Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.
Ellipsis Health
Series A in 2021
Ellipsis Health, Inc. is a technology company based in San Francisco, California, founded in 2013. It specializes in developing analytics solutions that utilize artificial intelligence to enhance behavioral health assessments by analyzing patient speech and clinical data. The company's platform offers a behavioral biomarker technology that generates clinical-grade evaluations of anxiety and depression severity, as well as sub-clinical assessments of stress. This innovative approach allows healthcare systems to continuously monitor their patient populations for mental health conditions, particularly depression, and facilitates timely support for patients in need. By integrating affective computing into patient and care team interactions, Ellipsis Health aims to create real-time behavioral health vital signs for improved patient outcomes.
Hello Heart
Series C in 2021
Hello Heart Inc. is a health technology company that offers a comprehensive application designed to help individuals manage their blood pressure effectively. Founded in 2013 and based in Redwood City, California, the company provides users with a wireless blood pressure monitor paired with a smartphone application that delivers real-time, personalized health tips. The application is particularly aimed at individuals with high blood pressure, empowering them to understand and improve their heart health. By facilitating self-management and promoting behavior change, Hello Heart seeks to prevent serious health risks associated with hypertension, which is a major cost factor for employers. The program is clinically based, ensuring that users receive reliable guidance in an engaging manner.
Clear Labs
Series C in 2021
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
Docbot
Series A in 2021
Docbot, Inc. is an artificial intelligence technology company based in Irvine, California, that specializes in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices, offering a clinical decision support system that aggregates patient information and provides cloud analytics for healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which focuses on real-time image analysis and automated reporting. This platform is designed to detect colorectal cancer and other gastrointestinal conditions by integrating various data sources from imaging systems and pathology requisitions. Docbot aims to enhance patient care and streamline clinical workflows, ultimately reducing cancer risks and improving outcomes for patients in the gastrointestinal specialty.
Apton Biosystems
Series A in 2021
Apton Biosystems, Inc., founded in 2012 and located in Pleasanton, California, operates within the biotechnology industry, focusing on advanced medical technology. The company has developed an innovative optical system for sequencing and protein detection that utilizes super-resolution techniques. This technology allows for the assessment of molecules situated closer than the wavelength of light, facilitating multi-omic sequencing and single-molecule protein detection. Apton's solutions aim to enhance biomarker discovery, enable early disease detection, and support therapeutic monitoring, thereby contributing to advances in preventive health and precision medicine.
turn.bio
Funding Round in 2021
Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.
Pendulum Therapeutics
Series C in 2021
Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.
Quadrant Eye
Seed Round in 2021
Quadrant Eye is an innovative company focused on transforming the field of online eye care. It has developed a comprehensive eye care platform that provides instant and reliable remote eye exams. This platform facilitates the screening, diagnosis, and management of various low-acuity and chronic eye conditions, such as cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy. By enabling patients to receive treatment for these conditions from the comfort of their homes, Quadrant Eye aims to enhance access to essential eye care services and improve patient outcomes.
StimScience
Seed Round in 2021
StimScience is an Electroceuticals company based in Berkeley, California, specializing in transcranial electrical stimulation (tES) technologies, including transcranial direct current stimulation, transcranial alternating current stimulation, and transcranial random noise stimulation. Founded in 2017, the company focuses on translating neuroscience and sleep research into practical products and services aimed at improving sleep quality and overall brain health. Their NeuroMod tXES system allows users to create custom waveforms for tES applications. StimScience's team comprises leading experts in sleep research and non-invasive brain stimulation, including prominent scientists and former employees from major tech companies. The company is developing Somnee, a diagnostic and therapeutic product designed to enhance sleep onset and quality. Recognizing the critical role of sleep in mental health, memory, and physical fitness, StimScience aims to address the widespread issue of sleep dissatisfaction affecting a significant portion of the adult population.
Rightway
Series C in 2021
Rightway is a technology and services company focused on simplifying healthcare for clients and their members. The company develops care navigation and pharmacy benefit management (PBM) solutions aimed at reducing healthcare spending by guiding members toward optimal care and therapies. Rightway's mission centers on using guidance and advocacy to lower costs and improve healthcare outcomes by aligning incentive models and integrating clinicians into the care journey. Its modern care navigation technology offers clinical guidance at a lower cost compared to traditional solutions. Additionally, Rightway's innovative PBM model ensures that every prescription is directed towards the lowest net cost, thereby minimizing expenses for members. The company’s transparent approach to pharmacy benefits is unique in that it incorporates care navigation, enhancing the overall member experience and engagement while addressing total cost-of-care.
Scipher Medicine
Series C in 2021
Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.
Inflammatix
Series D in 2021
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.
Forward
Series D in 2021
Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.
Bold
Seed Round in 2021
Bold is an at-home digital fitness program designed to help older adults live their strongest, happiest, and healthiest lives. As a member, you’ll enjoy instant access to expert trainers, scientific assessments, and personalized workout plans to help you improve your strength, flexibility, and balance — so you can chase the life you want, at any age.
Sword Health
Series B in 2021
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
Ukko
Series B in 2021
Ukko is a biotechnology company focused on enhancing the lives of individuals with food allergies and gluten-related disorders. Utilizing a sophisticated computational engineering platform, Ukko redesigns food allergens into therapeutics that are safe and effective. The company is developing a detailed, clinically validated map of the molecular structures associated with food allergies, which provides insights into the biological mechanisms of human-food interactions. By leveraging this information, Ukko creates modified proteins that do not provoke an immune response, offering a novel approach to treating protein-based allergies. Through the integration of artificial intelligence, immunology, computational biology, and protein engineering, Ukko aims to produce safe protein alternatives that physicians can confidently prescribe to patients.
Lumiata
Series B in 2021
Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.
Earli
Series A in 2021
Earli is a company focused on developing innovative cancer treatment devices that utilize synthetic biomarkers for early cancer detection. The company's approach involves a novel gene therapy technique known as Synthetic Biopsy, which prompts cancer cells to produce synthetic, non-human biomarkers. These biomarkers can be detected through various means, including blood, urine, or breath, allowing for timely tracking and treatment of cancer. By facilitating the early identification of cancer when it is still homogeneous, Earli aims to significantly enhance survival rates. Their technology not only aids in detection but is also applicable for therapeutic interventions, thereby personalizing treatment and improving patient outcomes.
Curai Health
Series B in 2020
Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.
Rubedo Life Sciences
Seed Round in 2020
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.
Advanced Chemotherapy Technologies
Series A in 2020
Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.
Siolta Therapeutics
Series B in 2020
Siolta Therapeutics, Inc. is a clinical-stage biotech company based in San Francisco, California, focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016, the company utilizes its expertise in the developing gut microbiome to promote immune tolerance. Siolta's platform includes the development of pharmaceutical-grade anaerobic organisms and microbiome-based diagnostics that support precision medicine. By leveraging insights from human microbiome studies, Siolta Therapeutics aims to create targeted microbial therapeutics that address the underlying causes of inflammatory diseases, enabling a new approach to prevention and treatment.
Invoy
Series A in 2020
Invoy is a company focused on providing personalized nutrition and wellness services through innovative monitoring medical devices. By utilizing science, data, and artificial intelligence, Invoy's technology captures real-time data on individual metabolism, allowing for tailored nutritional recommendations. The company aims to enhance individual health and weight loss goals by addressing the unique body chemistry of each person. With an emphasis on affordability, Invoy offers breath analyzers for medical applications, enabling users to effectively monitor their health and optimize their wellness journey.
Focal Medical
Series A in 2020
Focal Medical, Inc. is a privately held biopharmaceutical company based in Cary, North Carolina, specializing in the development of innovative drug delivery systems for challenging cancers. The company focuses on creating targeted therapeutic products, with its lead offering designed to deliver gemcitabine directly to the pancreas through non-circulatory pathways, specifically targeting pancreatic cancer. This approach combines iontophoresis with an implantable delivery system, allowing for precise chemotherapy delivery that aims to enhance patient recovery. In addition to pancreatic cancer, Focal Medical is also exploring therapies for other solid tumors and genomic medicine products, underscoring its commitment to advancing treatment options for difficult-to-treat cancers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.